In November 2015 the RiHN team hosted a Special Interest Group in partnership with Medilink . Those who attended had the opportunity to engage with researchers from various institutions who are leading cutting edge feasibility studies that have the potential to radically transform patient care and medical supply chains.
The event started with a welcome from Dr Steve Langron from Lime Associates (representing the Medilink EM SIG) and RiHN Network Director Dr Wendy Phillips. A key note presentation was delivered by Professor Nick Rich of Swansea University. This was followed by presentations by the network’s feasibility studies:
- Cell Microfactories: RDM of Cell-Based Therapeutics – presented by Prof Nick Medcalf from the University of Loughborough
- RDM for home-use medical devices – presented bypresented by Dr Alison Bray and Dr Javier Munguia from Newcastle Hospitals
- 3D Bioprinting of Islet Micro-tissues to RDM for Treatment of Type 1 Diabetes – presented by Dr Alex Popov from the University of Newcastle
- Enhancing the resilience of the vaccine supply chain: the role of RDM – presented by Sam Roscoe from the University of Sussex
- 3D Bioprinting: Commercialising Personalised ATMP/Device Combination Products – presented by Dr Andy Gleadall from the University of Nottingham
In the afternoon the participants had the opportunity to join break out groups, examining specific supply chain scenarios and opportunities from the perspective of each of the feasibility study teams. Using a standard template supplied by the Centre for International Manufacturing at the Cambridge Institute for Manufacturing, each group explored how existing stakeholders, value chains, and supply operations would be affected by RDM and how new models might emerge.
Further details about the programme, delegates and speakers are available to view on the Medilink website.